Roche's Renewed Effort: A Phase III Gene Therapy Trial for Duchenne Muscular Dystrophy

Roche announced on Thursday its plans to initiate a late-stage study for the gene therapy Elevidys, following feedback from European regulators. This comes after the therapy aimed at treating Duchenne muscular dystrophy (DMD) did not win the approval of the European Medicines Agency (EMA) last year, largely due to scrutiny arising from two patient deaths.

The phase III trial intends to gather the necessary placebo-controlled data for a potential regulatory re-submission to the EMA. Currently, Elevidys has approval in nine countries, including the United States, specifically for ambulatory boys diagnosed with a confirmed DMD mutation. Previously, the U.S. had temporarily suspended its distribution last July.

DMD, a rare inherited condition predominantly affecting boys, leads to a progressive weakening of muscles. The study, which will last over 72 weeks, aims to assess both the efficacy and safety of Elevidys compared to a placebo in approximately 100 young ambulatory boys with DMD. The main focus will be the change in the 'time to rise' from the floor velocity. Roche's Chief Medical Officer, Levi Garraway, emphasized their confidence in the therapy, citing robust long-term data and experiences from treating over a thousand boys globally.